


MURIEL HE

Fangda Partners

+86 21 6263 5863

muriel.he@fangdalaw.com



PRACTICE AREAS

MS. HE SPECIALIZES IN REGULATORY COMPLIANCE, GENERAL CORPORATE, PRIVATE EQUITY INVESTMENT, VENTURE CAPITAL AND M&A, WITH A STRONG TRACK RECORD IN VARIOUS INDUSTRY SECTORS SUCH AS PHARMA, LIFE SCIENCE, HEALTHCARE AND TMT.

REPRESENTATIVE MATTERS AND CASES

- Represented AstraZeneca in its granting exclusive commercialization rights to COVID-19 vaccine to Kangtai Bio
- Represented Biosensor in the import, registration, clinical trial and commercialization of its coronary stent in China
- Acted for Bristol-Myers Squibb China as external counsel for its whole product line in China, included acting on various regulatory compliance matters such as product registration, pre-clinical study, clinical trial, manufacture, promotion, commercialization, etc.
- Acted for Abbott China IVDC as external counsel for its whole product line in China, included acting on various regulatory compliance matters such as product registration, pre-clinical study, clinical trial, manufacture, promotion, etc.
- Represented Mylan in reorganizing its corporate structure to integrate with Pfizer Upjohn's China unit following Mylan's global acquisition of Pfizer Upjohn
- Represented Siemens Healthineers in reorganizing its China business structure for its pre-IPO restructuring
- Represented Shanghai Pharma Group and PDSTI in their offshore acquisitions in the US and Korea

- Represented Abbott China in reorganizing its corporate structure to integrate with St. Jude Medical's China unit following Abbott's global acquisition of St. Jude Medical
- Represented Tencent in its acquisition of 100% interest in "Xingren Doctor", a leading internet healthcare service platform in China
- Represented Beigene in its acquisition of 100% interest in Huajian Pharm
- Represented Fountain Vest in its Series B investment in "Xingren Doctor"
- Represented Boehringer Ingelheim in reorganizing its corporate structure to integrate with Merial Animal Health's China unit following Boehringer Ingelheim's global acquisition of Merial Animal Health department
- Represented Molbase, an integrated chemicals transaction platform, in its Series D financing from onshore and offshore vehicles
- Represented Starcrest Fund in its investments in several offshore startups
- Represented Abbott China in reorganizing its corporate structure to integrate with Alere Medical's China unit following Abbott's global acquisition of Alere Medical
- Represented GP Capital in its investments in the healthcare and life science sectors
- Represented Beigene in its granting exclusive commercialization rights to the pipeline (PD-1) monoclonal antibody BGB-A317 to Celgene
- Represented Boehringer Ingelheim in its collaboration with Shanghai International Medical Center on the Consanas Rehabilitation Center
- Represented Boehringer Ingelheim in its granting exclusive commercialization rights to Mucosolvan injectable solution to Zhejiang Biotech
- Represented multinational corporations BMS, AstraZeneca, Novartis, GE, MSD, GSK, Sanofi, Schlumberger, Boehringer Ingelheim, Biogen, Cstone, Assembly, Astellas, Mylan, Siemens, Catalent, Allergan, Hologic, Shire, Ferring and Tosh in various legal matters including general corporate, acquisitions, joint venture formation, regulatory compliance, intellectual property and corporate restructuring

OTHER INFORMATION

Education

- Washington University in St. Louis (WUSTL), School of Law, LL.M.
- Shanghai University of Finance and Economics, School of Law, LL.B.

- Shanghai University of Finance and Economics, School of Statistics, B.S.

Professional Qualification

- Admitted to practice in the PRC

Professional Background

Ms. He joined Fangda as in 2019. Before joining the firm, she worked at a top Chinese firm.